ORCHID PHARMA LTD – Q1 FY27 CONCALL HIGHLIGHTS
#Q1FY27
Q1FY27 Financial Performance
- Revenue from operations reached ₹304 Cr, up 15% YoY.
- Gross margin improved to 33% vs 30% YoY.
- EBITDA increased to ₹25 Cr vs ₹10 Cr.
- FY26 revenue stood at ₹1,233 Cr on combined basis.
- FY26 gross margin moderated to 32%.
- Cephalosporin pricing remains highly competitive.
- Industry continues to face significant overcapacity.
- Management remains focused on volume growth.
- Product mix improvement remains a key priority.
- Cost discipline remains firmly in focus.
Merger & Synergies
- Dhanuka Laboratories merger became effective 10 July 2026.
- Appointed date remains 1 April 2024.
- FY25 and FY26 numbers were restated.
- Combined platform provides greater diversification.
- Integration projects have already commenced.
- Initial synergy benefits expected from FY28.
- Cost savings remain a major integration objective.
- Management expects progressive profitability improvement.
Core Business Outlook
- Q1 FY27 performance showed early improvement.
- Industry pricing pressure remains elevated.
- Non-regulated markets remain highly competitive.
- Regulated-market demand is cyclical.
- Q1 regulated-market demand was described as mediocre.
- Management expects better regulated demand over next 2–3 quarters.
- Historically, H2 sees stronger regulated-market demand.
- No specific FY27 revenue-growth guidance provided.
- Management avoided giving a 20% growth target.
Xblyseb / Advanced Pharma
- Russia licensing arrangement estimated at $178 Mn over 10 years.
- This represents estimated long-term value, not current revenue.
- European vial volumes continue showing strong growth.
- Q3FY26 volume growth was 300% QoQ.
- Q4FY26 growth reached around 175% QoQ.
- Q1FY27 volumes increased another 50% QoQ.
- Big Five European markets have been launched.
- South Africa registration has been completed.
- GCC market coverage has been achieved.
- Middle East launch timing affected by regional conflict.
- Discussions underway across multiple international markets.
- Russia registration and launch may take 1.5–2 years.
- Long-term sales ambition remains $1.1–2 Bn.
7-ACA Project
- Jammu 7-ACA facility remains targeted for March 2027.
- Project capex is approximately ₹750 Cr.
- First commercial batch targeted by March 2027.
- Ramp-up expected to reach 80–100% within first year.
- Long-term utilization targeted at 80% captive / 20% third-party.
- Initial output will largely be captive.
- Third-party sales require customer GMP approvals.
- Management sees limited scope for drastic China price cuts.
- 7-ACA prices have remained stable for 10–12 years.
- Weighted average price is around $60.
- Technology partner supports production stabilization.
- Partner will continue developing improved strains.
- Management acknowledges fermentation ramp-up remains unpredictable.
- Pilot plant has already scaled 20x.
- Jammu requires further approximately 800x scale-up.
Cefiderocol Project
- Facility commissioning remains targeted for December 2026.
- Validation and initial batches follow commissioning.
- India launch depends on DCGI approval.
- First approval may take 6–9 months after facility readiness.
- India commercial operations could begin around Q3 FY28.
- GARDP global RFP process is underway.
- WHO prequalification remains a strategic objective.
- WHO PQ process may take around 2 years.
- Management is engaging stakeholders regarding trial waiver.
- Previous Orchid waiver provides some precedent.
US Injectable Strategy
- US strategy remains targeted around 2030.
- Six molecules identified for future opportunity.
- Three newer molecules include Cefta-Avi, Ceftaroline and Ceftolosine-Tazobactam.
- Older molecules include Cefepime, Ceftriaxone and Cefazolin.
- Generic filings will use Orchid's facility.
- Newer molecules may use CMOs initially.
- Meaningful launches are not expected before FY28.
- Validation, FDA approval and ANDA filings remain multi-year processes.
Cephalosporin Strategy
- Cefixime faces the strongest margin pressure.
- Pressure is mainly in rest-of-world markets.
- Cefuroxime and other 7-ACA products remain relatively stable.
- Orchid is diversifying beyond low-margin products.
- Company focuses on value-based rather than volume-led business.
- Orchid manufactures around 20–25 products.
- Competitors generally focus on fewer products.
- Backward and forward integration aim to de-risk APIs.
- 7-ACA and injectable capacity support this strategy.
- Ceftriaxone offers significant scaling opportunity.
- Orchid plans to supply non-sterile Ceftriaxone to other players.
- Competitors could become Orchid's customers.
AMS Business
- AMS revenue was approximately ₹5 Cr in Q1.
- EBITDA loss reduced to around ₹0.5 Cr.
- Quarterly drag has reduced significantly.
- Distribution network is being built for Cefiderocol.
- Distribution agreement discussions are at advanced stage.
NPMC / Synthetic Business
- NPMC sales were approximately ₹21 Cr in Q1.
- Company is developing additional high-value molecules.
- Backward integration is planned for select molecules.
- New products and capacity additions remain ongoing.
- Business continues to be developed incrementally.
CAPEX & Execution
- Major FY27 capex is focused on strategic projects.
- 7-ACA project requires ₹750 Cr.
- Cefiderocol project requires $20–25 Mn.
- Management expects project execution to remain disciplined.
- PLI benefit is currently expected for 2 years.
- Extension may be pursued after plant commencement.
- Capital allocation remains focused on strategic integration.
KEY TAKEAWAY
- Core recovery + 7-ACA/Cefiderocol create long-term upside.
1August 24, 2026 1.4K 2
